# LEGEND-2

Source: https://onco.cc/trials/legend-2/  
OnCo record `legend-2` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The small Chinese trial whose startling response rates at ASCO 2017 drew Johnson and Johnson to Legend Biotech and became the myeloma CAR-T Carvykti.

## Summary

57 patients treated at Xi'an Jiaotong University's Second Affiliated Hospital (Journal of Hematology and Oncology 2018): objective response 88%, complete response 68%, median progression-free survival 15 months, manageable cytokine release syndrome; a further 17 patients were treated at three other sites. Presented at ASCO 2017 by Fan Xiaohu and Zhao Wanhong, it led to the December 2017 Janssen collaboration ($350 million upfront) and to CARTITUDE-1, FDA approval as ciltacabtagene autoleucel in 2022 and NMPA approval in 2024. The clearest case of a Chinese academic-industry cell therapy becoming a global standard.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-10
- Tags: china
- Registry id: NCT03090659
- Phase: 1/2
- Setting: Relapsed or refractory multiple myeloma, four hospitals in China: LCAR-B38M, a BCMA CAR-T with two llama-derived binding domains
- Sponsor: Legend Biotech with Xi'an Jiaotong University and other Chinese hospitals
- Enrolled: 57
- Result: ORR 88%, CR 68%, median PFS 15 months (Xi'an cohort, n = 57).
- Outcomes: Objective response rate: LCAR-B38M 88%

## Sources

- ClinicalTrials.gov NCT03090659: https://clinicaltrials.gov/study/NCT03090659
- J Hematol Oncol 2018: https://doi.org/10.1186/s13045-018-0681-6

## Connected records

- trials: [CARTITUDE-1](https://onco.cc/trials/cartitude-1/), [CARTITUDE-4](https://onco.cc/trials/cartitude-4/)
- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/)
- drugs: [Ciltacabtagene autoleucel](https://onco.cc/drugs/ciltacabtagene-autoleucel/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/), [Legend Biotech](https://onco.cc/companies/legend-biotech/)
- people: [Fangliang (Frank) Zhang](https://onco.cc/people/zhang-fangliang/)
- key papers: [A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma](https://onco.cc/key-papers/paper-zhao-j-hematol-oncol/)

---
JSON: https://onco.cc/api/v1/entities/legend-2.json